Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Stoke Therapeutics, Inc

Clinical trials sponsored by Stoke Therapeutics, Inc, explained in plain language.

Stoke Therapeutics, Inc. STOK NASDAQ

A biopharmaceutical company developing RNA-based therapies for genetic diseases.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Not yet finished but already full! 1

New hope for kids with severe epilepsy: drug trial targets seizures

Disease control Recruiting now

This Phase 3 study tests a drug called zorevunersen in 170 children aged 2 to 17 with Dravet syndrome, a severe form of epilepsy. The drug is given as an injection into the spine and compared to a sham procedure. The goal is to see if it reduces seizures and improves daily living…

Phase: PHASE3 • Sponsor: Stoke Therapeutics, Inc • Aim: Disease control

Last updated Aug 07, 2026 00:00 UTC